NASDAQ:UMRX - Unum Therapeutics Stock Price, Forecast & News

Unum Therapeutics trades on the NASDAQ under the ticker symbol "UMRX."

Unum Therapeutics Inc (NASDAQ:UMRX) issued its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.33) by $0.07. The company had revenue of $1.02 million for the quarter, compared to analysts' expectations of $4.41 million. Unum Therapeutics had a negative net margin of 388.07% and a negative return on equity of 96.07%. View Unum Therapeutics' Earnings History.

Unum Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Unum Therapeutics.

5 brokers have issued 12-month target prices for Unum Therapeutics' stock. Their forecasts range from $3.00 to $18.00. On average, they anticipate Unum Therapeutics' stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 843.4% from the stock's current price. View Analyst Price Targets for Unum Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unum Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Unum Therapeutics.

Press coverage about UMRX stock has trended somewhat positive this week, InfoTrie reports. The research firm scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Unum Therapeutics earned a news impact score of 1.3 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Unum Therapeutics.

Unum Therapeutics saw a drop in short interest in the month of December. As of December 31st, there was short interest totalling 372,700 shares, a drop of 18.6% from the December 15th total of 457,600 shares. Based on an average daily volume of 308,100 shares, the short-interest ratio is currently 1.2 days. Approximately 2.9% of the company's shares are sold short. View Unum Therapeutics' Current Options Chain.

Some companies that are related to Unum Therapeutics include Zynerba Pharmaceuticals (ZYNE), Galmed Pharmaceuticals (GLMD), ProMetic Life Sciences (PFSCF), Northwest Biotherapeutics (NWBO), Paratek Pharmaceuticals (PRTK), Clearside Biomedical (CLSD), Chimerix (CMRX), Eton Pharmaceuticals (ETON), CV Sciences (CVSI), Marinus Pharmaceuticals (MRNS), OASMIA PHARMACE/ADR (OASM), Aduro BioTech (ADRO), NeuBase Therapeutics (NBSE), CELYAD SA/ADR (CYAD) and Scpharmaceuticals (SCPH).

Based on aggregate information from My MarketBeat watchlists, some companies that other Unum Therapeutics investors own include SCYNEXIS (SCYX), AzurRx BioPharma (AZRX), Strongbridge Biopharma (SBBP), Vistagen Therapeutics (VTGN), KemPharm (KMPH), Onconova Therapeutics (ONTX), Outlook Therapeutics (OTLK), Spring Bank Pharmaceuticals (SBPH), Sierra Oncology (SRRA) and Matinas BioPharma (MTNB).

(UMRX) raised $75 million in an IPO on Thursday, March 29th 2018. The company issued 5,800,000 shares at $12.00-$14.00 per share. Morgan Stanley and Cowen acted as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush Securities were co-managers.

Shares of UMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of UMRX stock can currently be purchased for approximately $1.06.

Unum Therapeutics has a market capitalization of $32.50 million and generates $9.73 million in revenue each year. The company earns $-34,530,000.00 in net income (profit) each year or ($1.39) on an earnings per share basis. Unum Therapeutics employs 56 workers across the globe.View Additional Information About Unum Therapeutics.

The official website for Unum Therapeutics is http://www.unumrx.com/.

Unum Therapeutics' mailing address is 200 CAMBRIDGE PARK DRIVE SUITE 3100, CAMBRIDGE MA, 02140. The company can be reached via phone at 617-945-5576 or via email at [email protected]